|
|
Blood, 1 January 2007, Vol. 109, No. 1, pp. 139-144.
Prepublished online as a Blood First Edition Paper on September 7, 2006; DOI 10.1182/blood-2006-04-014654.
 Previous Article | Next Article 
Submitted April 4, 2006
Accepted August 9, 2006
Homocysteine lowering by B vitamins and the secondary
prevention of deep-vein thrombosis and pulmonary
embolism. A randomized, placebo-controlled, double blind
trial
Martin den Heijer*, Huub PJ Willems, Henk J Blom, Wim BJ Gerrits, Marco Cattaneo, Sabine Eichinger, Frits R. Rosendaal, and Gerard MJ Bos
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Dept. of Hematology, Leyenburg Hospital, The Hague, The Netherlands
Laboratory of Paediatrics and Neurology, Radboud University Nijmegen Medical Centre, Nijmegen
Unit of Hematology and Thrombosis, Ospedale San Paolo, University of Milano, Milano, Italy
Dept. of Internal Medicine I, Medical University of Vienna, Vienna, Austria
Dept. of Clinical Epidemiology and Dept. of Hematology, Leiden University Medical Center, Leiden
Dept. of Hematology, University Hospital Maastricht, Maastricht, The Netherlands
* Corresponding author; email: m.denheijer{at}endo.umcn.nl.
The VITRO (Vitamins and Thrombosis) study investigated the effect of homocysteine lowering by daily supplementation of B-vitamins on the risk reduction of deep-vein thrombosis and pulmonary embolism. Patients between 20 to 80 years old with a first objectively confirmed proximal deep-vein thrombosis or pulmonary embolism in the absence of major risk factors and a homocysteine concentration above the 75th percentile of a reference group were asked to participate (hyperhomocysteinemic group). A similar study was conducted in a random sample of patients with a homocysteine below the 75th percentile of the reference group (normohomocysteinemic group). After informed consent patients were randomized to daily multivitamin supplementation (5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin) or placebo and were followed for 2.5 years. End-points were objectively diagnosed recurrent deep-vein thrombosis or pulmonary embolism. A total of 701 patients were enrolled (360 in the hyper- and 341 in the normo homocysteinemic group). The number of recurrent events of venous thrombosis was 43 out of 353 in the vitamin group (54/1000yr) and 50 out of 348 in the placebo group (64/1000yr ). The hazard ratio associated with vitamin treatment was 0.84 (95%CI 0.56-1.26): 1.14 (95%CI 0.65-1.98) in the hyperhomocysteinemic group and 0.58 (95%CI 0.31-1.07) in the normohomocysteinemic group. The results of our study do not show that homocysteine lowering by B-vitamin supplementation prevents recurrent venous thrombosis. (ClinicalTrials.gov number NCT00314990)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Vitamins and Thrombosis (VITRO) study—homocysteine lowering with B vitamins
- Antonis Georg Tsamaloukas
Blood 2007 109: 5520-5521.
[Full Text]
[PDF]
-
Response: Homocysteine lowering and recurrent venous thrombosis: the VITRO trial
- Martin den Heijer, Henk J. Blom, Frits R. Rosendaal, and Gerard M. J. Bos
Blood 2007 109: 5521-5522.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
V. Ducros, C. Barro, J. Yver, G. Pernod, B. Polack, P. Carpentier, M.-D. Desruet, and J.-L. Bosson
Should Plasma Homocysteine Be Used as a Biomarker of Venous Thromboembolism? A Case--Control Study
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2009;
15(5):
517 - 522.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Hotoleanu, O. Andercou, and A. Andercou
Mesenteric Venous Thrombosis With Bowel Infarction and Hyperhomocysteinemia Due to Homozygous Methylenetetrahydrofolate Reductase C677T Genotype
Vascular and Endovascular Surgery,
October 1, 2008;
42(5):
477 - 481.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Dayal and S. R. Lentz
Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes
Arterioscler Thromb Vasc Biol,
September 1, 2008;
28(9):
1596 - 1605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Rodionov and S. R. Lentz
The Homocysteine Paradox
Arterioscler Thromb Vasc Biol,
June 1, 2008;
28(6):
1031 - 1033.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.-Y. Chang, S.-C. Lu, C.-M. Lee, Y.-J. Chen, T. A. Dugan, W.-H. Huang, S.-F. Chang, W. S.L. Liao, C.-H. Chen, and Y.-T. Lee
Homocysteine Inhibits Arterial Endothelial Cell Growth Through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation
Circ. Res.,
April 25, 2008;
102(8):
933 - 941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ryan-Harshman and W. Aldoori
Vitamin B12 and health
Can Fam Physician,
April 1, 2008;
54(4):
536 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Lijfering, N. J.G.M. Veeger, J.-L. P. Brouwer, and J. van der Meer
The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels
Haematologica,
December 1, 2007;
92(12):
1703 - 1706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hron, R. Lombardi, S. Eichinger, A. Lecchi, P. A. Kyrle, and M. Cattaneo
Low vitamin B6 levels and the risk of recurrent venous thromboembolism
Haematologica,
September 1, 2007;
92(9):
1250 - 1253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Marcucci, F. Sofi, A. M. Gori, G. F. Gensini, and R. Abbate
Vitamin supplementation in the secondary prevention of venous thromboembolism: about the VITRO study
Blood,
June 15, 2007;
109(12):
5520 - 5520.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Tsamaloukas
Vitamins and Thrombosis (VITRO) study--homocysteine lowering with B vitamins
Blood,
June 15, 2007;
109(12):
5520 - 5521.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Ray, C. Kearon, Q. Yi, P. Sheridan, E. Lonn, and for the Heart Outcomes Prevention Evaluation 2 (HO
Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism: A Randomized Trial
Ann Intern Med,
June 5, 2007;
146(11):
761 - 767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bathum, I. Petersen, L. Christiansen, A. Konieczna, T. I.A. Sorensen, and K. O. Kyvik
Genetic and Environmental Influences on Plasma Homocysteine: Results from a Danish Twin Study
Clin. Chem.,
May 1, 2007;
53(5):
971 - 979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. D. Bezemer, C. J. M. Doggen, H. L. Vos, and F. R. Rosendaal
No Association Between the Common MTHFR 677C->T Polymorphism and Venous Thrombosis: Results From the MEGA Study
Arch Intern Med,
March 12, 2007;
167(5):
497 - 501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Homocysteine-Lowering Therapy After Venous Thromboembolism
Journal Watch (General),
February 6, 2007;
2007(206):
1 - 1.
[Full Text]
|
|
|
|
|
|
|
Venous Thrombosis: The Culprit Is Factor VIII, not Homocysteine
Journal Watch Oncology and Hematology,
January 22, 2007;
2007(122):
6 - 6.
[Full Text]
|
|
|
|
|
